Physician profile
Iris Veronica Carson
NPI 1144974270
$586.58
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $446 · 2023: $120 · 2024: $20.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $134.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.76 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $60.08 | 2022-2023 | Soliris |
| Amgen INC. | $55.36 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $42.90 | 2022-2023 | Lokelma |
| Opko Pharmaceuticals, LLC | $35.16 | 2022 | |
| Daiichi Sankyo INC. | $24.51 | 2023 | Injectafer |
| Calliditas Therapeutics US INC. | $20.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.13 | 2024 | Xarelto |
| Fresenius USA Marketing, INC. | $19.88 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.48 | 2022 | |
| Travere Therapeutics, INC. | $13.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.